These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15014684)

  • 1. Zaleplon, A Novel Nonbenzodiazepine Hypnotic, Effectively Treats Insomnia in Elderly Patients Without Causing Rebound Effects.
    Ancoli-Israel S; Walsh JK; Mangano RM; Fujimori M
    Prim Care Companion J Clin Psychiatry; 1999 Aug; 1(4):114-120. PubMed ID: 15014684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group.
    Elie R; Rüther E; Farr I; Emilien G; Salinas E
    J Clin Psychiatry; 1999 Aug; 60(8):536-44. PubMed ID: 10485636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group.
    Fry J; Scharf M; Mangano R; Fujimori M
    Int Clin Psychopharmacol; 2000 May; 15(3):141-52. PubMed ID: 10870872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group.
    Hedner J; Yaeche R; Emilien G; Farr I; Salinas E
    Int J Geriatr Psychiatry; 2000 Aug; 15(8):704-12. PubMed ID: 10960882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zaleplon: a review of its use in the treatment of insomnia.
    Dooley M; Plosker GL
    Drugs; 2000 Aug; 60(2):413-45. PubMed ID: 10983740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia.
    Walsh JK; Vogel GW; Scharf M; Erman M; William Erwin C ; Schweitzer PK; Mangano RM; Roth T
    Sleep Med; 2000 Feb; 1(1):41-49. PubMed ID: 10733619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized, comparative study to evaluate the efficacy and safety of zaleplon versus zolpidem in shortening sleep latency in primary insomnia.
    Huang YS; Hsu SC; Liu SI; Chen CK
    Chang Gung Med J; 2011; 34(1):50-6. PubMed ID: 21392474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of zaleplon in the treatment of insomnia.
    Ebbens MM; Verster JC
    Nat Sci Sleep; 2010; 2():115-26. PubMed ID: 23616704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia.
    Najib J
    Clin Ther; 2006 Apr; 28(4):491-516. PubMed ID: 16750462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening.
    Zammit GK; Corser B; Doghramji K; Fry JM; James S; Krystal A; Mangano RM
    J Clin Sleep Med; 2006 Oct; 2(4):417-23. PubMed ID: 17557470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia.
    Scharf MB; Roth T; Vogel GW; Walsh JK
    J Clin Psychiatry; 1994 May; 55(5):192-9. PubMed ID: 8071269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
    Roth T; Soubrane C; Titeux L; Walsh JK;
    Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia.
    Holm KJ; Goa KL
    Drugs; 2000 Apr; 59(4):865-89. PubMed ID: 10804040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eight weeks of non-nightly use of zolpidem for primary insomnia.
    Walsh JK; Roth T; Randazzo A; Erman M; Jamieson A; Scharf M; Schweitzer PK; Ware JC
    Sleep; 2000 Dec; 23(8):1087-96. PubMed ID: 11145323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eszopiclone (Lunesta): a new nonbenzodiazepine hypnotic agent.
    Brielmaier BD
    Proc (Bayl Univ Med Cent); 2006 Jan; 19(1):54-9. PubMed ID: 16424933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot controlled double-blind study of the hypnotic effects of zolpidem in patients with chronic 'learned' insomnia: psychometric and polysomnographic evaluation.
    Herrmann WM; Kubicki ST; Boden S; Eich FX; Attali P; Coquelin JP
    J Int Med Res; 1993; 21(6):306-22. PubMed ID: 8143886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent.
    Patat A; Paty I; Hindmarch I
    Hum Psychopharmacol; 2001 Jul; 16(5):369-392. PubMed ID: 12404558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of zaleplon in the treatment of insomnia.
    Israel AG; Kramer JA
    Ann Pharmacother; 2002 May; 36(5):852-9. PubMed ID: 11978165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zaleplon: a pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia.
    Weitzel KW; Wickman JM; Augustin SG; Strom JG
    Clin Ther; 2000 Nov; 22(11):1254-67. PubMed ID: 11117652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The need for flexibility in dosing of hypnotic agents.
    Doghramji K
    Sleep; 2000 Feb; 23 Suppl 1():S16-20; discussion S21-2. PubMed ID: 10755804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.